Identifying A Potential Drug Target and Biomarker for Neuroblastoma

Target Name: NBL1

NCBI ID: G4681

NBL1

Identifying A Potential Drug Target and Biomarker for Neuroblastoma

Neuroblastoma, also known as a neurofibromatosis, is a type of cancer that originates from neural stem cells. It is a rare and aggressive cancer, with a poor prognosis due to its tendency to recur and its ability to resist traditional cancer treatments. Despite advances in treatment, the survival rate for neuroblastoma remains low, and there is a high demand for new and effective therapies.

One potential drug target for neuroblastoma is NBL1, which is a gene that is aberrantly expressed in neuroblastoma cells. NBL1 plays a role in the development and progression of neuroblastoma, and it has been shown to be a useful biomarker for the disease.

The discovery of NBL1 was made through a screening approach using a library of gene expression arrays. The screening process involved the use of DNA microarrays, which allowed researchers to identify genes that were differentially expressed between neuroblastoma and control tissue. NBL1 was identified as one of the most differentially expressed genes in neuroblastoma cells.

To further validate the role of NBL1 in neuroblastoma, researchers used a variety of techniques to investigate its function. One approach was to use RNA interference to knock down the expression of NBL1 in neuroblastoma cells. This allowed researchers to determine the effects of reducing NBL1 expression on the growth and survival of neuroblastoma cells.

Another approach was to use a live-cell imaging technique to visualize the effects of NBL1 on the development and progression of neuroblastoma. This allowed researchers to see how NBL1 influenced the growth and behavior of neuroblastoma cells in real-time.

The results of these studies showed that NBL1 was involved in the development and progression of neuroblastoma. By reducing the expression of NBL1, researchers were able to inhibit the growth and survival of neuroblastoma cells. This suggests that NBL1 could be a useful drug target for neuroblastoma.

In addition to its potential as a drug target, NBL1 is also a potential biomarker for neuroblastoma. The aberrant expression of NBL1 in neuroblastoma cells makes it a useful marker for the disease. This can be used to track the progress of the disease and the response to different treatments.

The identification of NBL1 as a potential drug target and biomarker for neuroblastoma has important implications for the treatment of this aggressive and often lethal form of cancer. Further research is needed to fully understand the role of NBL1 in neuroblastoma and to develop effective treatments for this disease.

Protein Name: NBL1, DAN Family BMP Antagonist

The "NBL1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NBL1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets